CervoMed Inc. Common Stock CRVO · Stock Open CervoMed Inc. Common Stock in new tab
CervoMed Inc. Common Stock Analysis (CRVO)
Is CervoMed Inc. Common Stock a good investment? CervoMed Inc. Common Stock (CRVO) is currently trading at 2.41 USD. Market analysts have a consensus price target of 15.40 USD. This suggests a potential upside from current levels.
Earnings Schedule: CervoMed Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -1.48.
Investor FAQ
Does CervoMed Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is CervoMed Inc. Common Stock?
CervoMed Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -3.21.
Company Profile
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the bloodbrain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| Aug. 3, 2005 | Needs review |
| March 10, 2014 | 1:100 |
| Aug. 19, 2016 | 1:10 |
| Dec. 14, 2018 | 0.07 |
| April 19, 2022 | 1:50 |
| Aug. 17, 2023 | 0.67 |
Community Discussion